(Q33606079)

28 July 2017

1 reference

title

A comparative review of new antipsychotics (English)

1 reference

28 July 2017

O Blin

1

1 reference

PubMed ID

10225124

28 July 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Canadian Journal of Psychiatry

28 July 2017

1 reference

28 July 2017

44

1 reference

28 July 2017

235-244

1 reference

28 July 2017

3

1 reference

Overview: maintenance therapy in psychiatry: I. Schizophrenia

28 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Serotonin-dopamine interaction and its relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Withdrawal syndromes associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Patient response and resource management: another view of clozapine treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Risperidone: review and assessment of its role in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Seroquel: biochemical profile of a potential atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Seroquel: electrophysiological profile of a potential atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674379904400303

10.1177/070674379904400303

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10225124